Talk:Gilteritinib
Latest comment: 3 years ago by Senior Science in topic Chemical structure error
| This is the talk page for discussing improvements to the Gilteritinib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Gilteritinib.
|
Clinical trial edit
Results from the ADMIRAL clinical trial : Gilteritinib new standard of care for relapsed, refractory FLT3-mutated acute myeloid leukemia - Rod57 (talk) 14:15, 1 November 2019 (UTC)
Chemical structure error edit
There is an error in the chemical structure. It should be a diamino-pyrazine in the molecule. See the Oncotarget reference for the correct structure....
Kawase T., Nakazawa T., Eguchi T., Tsuzuki H., Ueno Y., Amano Y., Suzuki T., Mori M., Yoshida T. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. Oncotarget. 2019; 10: 6111-6123 --Senior Science (talk) 13:49, 14 October 2020 (UTC)